ALBERT DAVID
|
|
BOM : 524075     NSE : ALBERTDAVD     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : None or < 25% |
Jul 05,2022 |
Price(EOD): ₹ 538.60
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 307.00 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ALBERT DAVID | 1.9% | -0.3% | 9.8% |
SUN PHARMACEUTICAL INDUSTRIES | -0.3% | -3% | 21% |
DIVIS LABORATORIES | 0.7% | 3.1% | -16.5% |
DR REDDYS LABORATORIES | 0.6% | 1.9% | -19.6% |
CIPLA | -0.8% | -3.9% | -4.9% |
GLAND PHARMA | -4.6% | -11.1% | -23% |
PIRAMAL ENTERPRISES | 2% | -5.5% | -29.9% |
CADILA HEALTHCARE | 1.5% | -0.9% | -43.6% |
TORRENT PHARMACEUTICALS | 1.8% | 4.2% | -0.7% |
FUNDAMENTAL ANALYSIS OF ALBERT DAVID
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ALBERT DAVID
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
13.88
P/E Calculated based on EPS of 38.8
[ Mar2021 - Standalone Results ] 1.26
P/B Calculated based on Book Value of 428.2
[ Mar2021 - Standalone Results ] 0.98
P/S Calculated based on Revenues of 313.512 Cr
[ TTM - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
55% 28% 42% |
SHARE PRICE MOMENTUM OF ALBERT DAVID
ALBERT DAVID vs SENSEX
DEBT OF ALBERT DAVID
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.01 0.01 0 0.01 |
- - - - |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ALBERT DAVID
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ALBERT DAVID
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
3.73% 37.91% -37.74% -47.59% |
31.08% 51.89% -23.52% -42.75% |
QtrlyTrend |
0 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
ALBERT DAVID related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 0.2% | -1.2% | -14.9% |
S&P BSE SMALL CAP | 0.2% | -5.2% | -0.9% |
S&P BSE ALLCAP | -0% | -4.4% | 0.1% |
S&P BSE MIDSMALLCAP | -0.1% | -4.5% | -1.7% |
You may also like the below Video Courses
FAQ about ALBERT DAVID
Is ALBERT DAVID good for long term investment?
As on Jul 05,2022, the Fundamentals of ALBERT DAVID look Poor and hence it may not be good for long term investment ! See Financial Performance of ALBERT DAVID . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ALBERT DAVID UnderValued or OverValued?
As on Jul 05,2022, ALBERT DAVID is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ALBERT DAVID ?
As on Jul 05,2022, the Intrinsic Value of ALBERT DAVID is Rs. 378.73 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 347.28
Fair Value [Median EV / Sales Model] : Rs. 421.93
Fair Value [Median Price / Sales Model] : Rs. 378.73
Median Fair Value of ALBERT DAVID : Rs. 378.73
Is ALBERT DAVID trading at a Premium or Discount?
As on Jul 05,2022, ALBERT DAVID is trading at a Premium of 42% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
